|
|
|
OCUL Description — Ocular Therapeutix Inc
Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co. also has product candidates in preclinical and clinical development designed to utilize its bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease.
Company Name: |
Ocular Therapeutix Inc |
Website: |
www.ocutx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding OCUL: |
19 |
Total Market Value Held by ETFs: |
$84,795,566 |
Total Market Capitalization: |
$1,399,000,000 |
% of Market Cap. Held by ETFs: |
6.06% |
|
ETF |
OCUL Weight |
OCUL Amount |
VTI |
0.00% |
$30,030,049 |
IWM |
0.04% |
$25,318,111 |
VXF |
0.01% |
$10,836,963 |
IWO |
0.08% |
$9,156,422 |
VTWO |
0.03% |
$2,666,517 |
IWC |
0.26% |
$2,291,082 |
XPH |
0.62% |
$1,378,648 |
ITOT |
0.00% |
$1,182,353 |
VTWG |
0.06% |
$647,536 |
RYJ |
0.54% |
$634,791 |
List of all 19 ETFs holding OCUL
» |
|
|
|
|
Strong Buy (3.78 out of 4)
71st percentile
|
|
|